SUPERNUS PHARMACEUTICALS, INC. (SUPN) Return on equity 2016–2025
SUPERNUS PHARMACEUTICALS, INC. (SUPN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-3.6%FY2025 · since FY2016: 47.6% → -3.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -3.6% | -10.8 pp |
| FY2024 | 7.1% | +7.0 pp |
| FY2023 | 0.1% | -6.7 pp |
| FY2022 | 6.9% | +0.3 pp |
| FY2021 | 6.5% | -10.5 pp |
| FY2020 | 17.0% | -1.9 pp |
| FY2019 | 19.0% | -5.5 pp |
| FY2018 | 24.5% | +3.1 pp |
| FY2017 | 21.4% | -26.2 pp |
| FY2016 | 47.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SUPN financial trends
SUPN RevenueSUPN Net incomeSUPN Net marginSUPN Gross profitSUPN Gross marginSUPN Operating incomeSUPN Operating marginSUPN Operating cash flowSUPN Free cash flowSUPN Capital expendituresSUPN Stock buybacksSUPN Dividends paidSUPN Total assetsSUPN Total liabilitiesSUPN Shareholders’ equitySUPN overview →